TABLE 2.
Patient reports on secondary study outcomes (attempt to quit smoking, point prevalence abstinence) at follow-up week 4, 12 and 26, stratified by pre/post data collection period and by training method of the GP they had consulted at baseline; and associations of these outcomes with training (post versus pre) and its interaction with the training method (ABC versus 5As by post versus pre); imputed data
Outcome (patient-reported) | Pre-training % | Post-training % | aORimputed post versus pre (95% CI)# | aRORimputed ABC versus 5As# by post versus pre (95%CI) | ||||
PreABC | Pre5As | Pretotal | PostABC | Post5As | Posttotal | |||
Quit attempt at week 4 | 19.4 | 18.7 | 19.0 | 21.4 | 15.5 | 18.7 | 0.95 (0.67–1.35) | 1.17 (0.64–2.13) |
Quit attempt at week 12 | 25.8 | 28.1 | 26.9 | 30.6 | 21.6 | 26.5 | 1.02 (0.72–1.45) | 1.12 (0.65–1.93) |
Quit attempt at week 26 | 29.1 | 29.5 | 29.3 | 28.8 | 20.5 | 24.9 | 0.88 (0.57–1.38) | 1.07 (0.63–1.83) |
Point prevalence abstinence at week 4 | 6.3 | 5.6 | 6.0 | 8.8 | 2.6 | 5.9 | 0.99 (0.50–1.97) | 1.64 (0.53–5.10) |
Point prevalence abstinence at week 12 | 9.9 | 11.8 | 10.9 | 12.6 | 0.8 | 7.1 | 0.70 (0.38–1.26) | 1.71 (0.75–3.91) |
Point prevalence abstinence at week 26 | 10.0 | 14.1 | 12.0 | 13.8 | 5.1 | 9.7 | 1.00 (0.51–1.95) | 1.51 (0.62–3.67) |
Data are presented as imputed percentages, adjusted odds ratios (aOR), and adjusted ratios of the odds ratios (aROR) and 95% confidence interval (95% CI) around aOR and aROR. Since multiple imputation was used, no absolute numbers are reported within this table.
#Logistic regression models with a fixed effect for time (post- versus pre-training) and random intercepts and slopes (for the time effect) for the practices; for the ABC versus 5As comparison: the group variable (ABC versus 5As training) and its interaction with time were added to the models as fixed effects; both models were adjusted for patients’ sex, age, level of education, time spent with urges to smoke and strength of urges to smoke (Strength of Urges to Smoke Scale [25]).